BALA CYNWYD, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Enfusion, Inc. (NYSE – ENFN)
Under the terms of the agreement, Enfusion will be acquired by Clearwater Analytics (“Clearwater”) (NYSE – CWAN) for $11.25 per share in cash in a deal worth approximately $1.5 billion. The investigation concerns whether the Enfusion Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.
Additional information can be found at https://www.brodskysmith.com/cases/enfusion-inc-nyse-enfn/.
Intra-Cellular Therapies, Inc. (Nasdaq – ITCI)
Under the terms of the Merger Agreement, ITCI will be acquired by Johnson & Johnson (NYSE – JNJ) for $132.00 per share in cash for a total equity value of approximately $14.6 billion. The investigation concerns whether the ITCI Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.
Additional information can be found at https://www.brodskysmith.com/cases/intra-cellular-therapies-inc-nasdaq-itci/.
Paycor HCM, Inc. (Nasdaq – PYCR)
Under the terms of the agreement, Paycor will be acquired by Paychex, Inc. (“Paychex”) (Nasdaq: PAYX) for $22.50 per share in cash for each Paycor share, representing an enterprise value of approximately $4.1 billion. The investigation concerns whether the Paycor Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.
Additional information can be found at https://www.brodskysmith.com/cases/paycor-hcm-inc-nasdaq-pycr/.
Accolade, Inc. (Nasdaq – ACCD)
Under the terms of the agreement, Accolade will be acquired by Transcarent for $7.03 per share in cash for each Accolade share, for an approximate equity value of $621 million. The investigation concerns whether the Accolade Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.
Additional information can be found at https://www.brodskysmith.com/cases/accolade-inc-nasdaq-accd/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
